|
Apr 15
|
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for April 2024
|
|
Apr 10
|
Can Recursion Pharmaceuticals Stock Double in 5 Years? Here's What It Would Take.
|
|
Apr 8
|
The AI Advantage: 2 Healthcare Stocks at the Forefront of Innovation
|
|
Apr 4
|
Is This Under-the-Radar Artificial Intelligence (AI) Stock a Buy?
|
|
Apr 4
|
Recursion Pharmaceuticals Inc Director Blake Borgeson Sells 11,447 Shares
|
|
Apr 3
|
Down -26.36% in 4 Weeks, Here's Why Recursion Pharmaceuticals (RXRX) Looks Ripe for a Turnaround
|
|
Apr 1
|
All You Need to Know About Recursion Pharmaceuticals (RXRX) Rating Upgrade to Buy
|
|
Mar 26
|
Recursion Publishes Annual Environmental, Social and Governance Report
|
|
Mar 18
|
New COVID-Like Outbreak 'Matter Of When, Not If,' WHO Director Warns As Scientists Race To Prepare Using Artificial Intelligence
|
|
Mar 15
|
Recursion Pharmaceuticals Inc CFO Michael Secora Sells 50,000 Shares
|
|
Mar 11
|
Recursion Announces Plans to Open New Office in London
|
|
Mar 7
|
Recursion Pharmaceuticals Stock Has 33% Upside, According to 1 Wall Street Analyst
|
|
Mar 1
|
Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community
|
|
Mar 1
|
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates
|
|
Feb 28
|
Why Recursion Pharmaceuticals Stock Dived by Nearly 17% Today
|
|
Feb 28
|
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2023 Earnings Call Transcript
|
|
Feb 27
|
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Lags Revenue Estimates
|
|
Feb 27
|
Recursion Pharmaceuticals Inc (RXRX) Reports Mixed Financial Results Amidst Advancements in ...
|
|
Feb 27
|
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results
|
|
Jan 29
|
20 Countries With The Highest Life Expectancy in the World
|